News >

EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC

Gina Columbus @ginacolumbusonc
Published: Monday, Feb 04, 2019

Dr. Roy Baynes

Roy Baynes, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for first-line treatment with pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) in patients with metastatic squamous non–small cell lung cancer (NSCLC).1

The decision is based on findings from the phase III KEYNOTE-407 trial, in which patients were enrolled regardless of PD-L1 expression status. Results showed that there was a significant improvement in progression-free and overall survival (OS) for those who received the combination versus chemotherapy alone.2,3

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication